SEARCH:   Advanced

Blood, 15 December 2004, Vol. 104, No. 13, pp. 4245-4251. Prepublished online as a Blood First Edition Paper on August 19, 2004; DOI 10.1182/blood-2004-03-0826. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-03-0826v1 104/13/4245    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Baccarani, M. Articles by Saglio, G. Search for Related Content PubMed PubMed Citation Articles by Baccarani, M. Articles by Saglio, G. Related Collections Neoplasia Oncogenes and Tumor Suppressors Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Imatinib and pegylated human recombinant interferon-2b in early chronic-phase chronic myeloid leukemia Michele Baccarani, Giovanni Martinelli, Gianantonio Rosti, Elena Trabacchi, Nicoletta Testoni, Simona Bassi, Marilina Amabile, Simona Soverini, Fausto Castagnetti, Daniela Cilloni, Barbara Izzo, Antonio de Vivo, Emanuela Messa, Francesca Bonifazi, Angela Poerio, Simona Luatti, Emilia Giugliano, Daniele Alberti, Gianluca Fincato, Domenico Russo, Fabrizio Pane, and Giuseppe Saglio, for the GIMEMA Working Party on Chronic Myeloid Leukemia From the Institute of Hematology and Medical Oncology "L. and A. Seràgnoli," University of Bologna; the Division of Hematology and Internal Medicine, Department of Clinical and Biological Science, University of Torino; CEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Napoli Federico II; Novartis Pharma, Origgio, Italy; Schering-Plough, Milan, Italy; and Chair of Hematology, University of Brescia, Italy. Since interferon- and imatinib (IM; STI571, Glivec, Gleevec) are effective for the treatment of chronic myeloid leukemia (CML), and their mechanisms of action are different, we designed an exploratory study investigating the effects of a standard IM dose (400 mg/d) and a variable pegylated interferon- (PegIFN) dose (50 µg/wk, 100 µg/wk, and 150 µg/wk). The criteria for dose adjustment were designed so as to ensure the delivery of the IM dose and to protect life quality. There were 76 patients with previously untreated Philadelphia (Ph)–positive CML enrolled in the study. There were 3 patients who discontinued IM and 45 patients who discontinued PegIFN. The severity of adverse events increased with increasing PegIFN dose. The IM dose could be administered to the patients who were assigned to receive 50 µg/wk or 100 µg/wk PegIFN but not to those who were assigned to receive 150 µg/wk. The median administered dose of PegIFN ranged between 32 µg/wk and 36 µg/wk. The cytogenetic response was 70% complete (Ph-neg 100%) and 83% major (Ph-neg > 65%). The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. E. Cortes Imatinib Therapy for Chronic Myeloid Leukemia: Where Do We Go Now? J. Clin. Oncol., July 10, 2008; 26(20): 3308 - 3309. [Full Text] [PDF] F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, A. Poerio, M. Amabile, M. Breccia, T. Intermesoli, F. Iuliano, G. Rege-Cambrin, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome Haematologica, May 1, 2008; 93(5): 770 - 774. [Abstract] [Full Text] [PDF] M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF] F. Palandri, I. Iacobucci, F. Quarantelli, F. Castagnetti, D. Cilloni, M. Baccarani, and on behalf of the GIMEMA Working Party on CML Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase Haematologica, November 1, 2007; 92(11): 1579 - 1580. [Abstract] [Full Text] [PDF] G. Rosti, I. Iacobucci, S. Bassi, F. Castagnetti, M. Amabile, D. Cilloni, A. Poerio, S. Soverini, F. Palandri, G. R. Cambrin, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party Haematologica, January 1, 2007; 92(1): 101 - 105. [Abstract] [Full Text] [PDF] M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, September 15, 2006; 108(6): 1809 - 1820. [Abstract] [Full Text] [PDF] L. Roy, J. Guilhot, T. Krahnke, A. Guerci-Bresler, B. J. Druker, R. A. Larson, S. O'Brien, C. So, G. Massimini, and F. Guilhot Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials Blood, September 1, 2006; 108(5): 1478 - 1484. [Abstract] [Full Text] [PDF] S. Parmar, J. Smith, A. Sassano, S. Uddin, E. Katsoulidis, B. Majchrzak, S. Kambhampati, E. A. Eklund, M. S. Tallman, E. N. Fish, et al. Differential regulation of the p70 S6 kinase pathway by interferon {alpha} (IFN{alpha}) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells Blood, October 1, 2005; 106(7): 2436 - 2443. [Abstract] [Full Text] [PDF] M. Deininger, E. Buchdunger, and B. J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood, April 1, 2005; 105(7): 2640 - 2653. [Abstract] [Full Text] [PDF] M. W.N. Deininger Management of Early Stage Disease Hematology, January 1, 2005; 2005(1): 174 - 182. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020